Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease - Wikidata - awgldk - TriplyDB

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

http://www.wikidata.org/entity/Q33911859

about

Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.Acetylcholinesterase inhibitors: pharmacology and toxicology.Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System Advances in designs for Alzheimer's disease clinical trials.Dementia in the oldest old: a multi-factorial and growing public health issue.Ethanolic Extract of the Seed of Zizyphus jujuba var. spinosa Ameliorates Cognitive Impairment Induced by Cholinergic Blockade in Mice.High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.Alzheimer's disease drug development: translational neuroscience strategies.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Transdermal donepezil on the treatment of Alzheimer's disease.The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice.Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents.Cognitive Ameliorating Effect of Acanthopanax koreanum Against Scopolamine-Induced Memory Impairment in Mice.Donepezil-related intractable hiccups: a case report.A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.

P2860

Q26851862-A85FDFB9-1E6C-4496-BEF6-6313BCA3A65E Q28067006-F449C37D-F94C-41BF-91B1-013D2DCED060 Q34297733-C31942F3-78A6-4188-A4F8-1403394735D1 Q34381860-BEE1A3DB-09D9-4C3D-96C7-98C16837F3DF Q34463351-AED85198-C0B1-4922-8157-3918C0B646FE Q34549155-FC766F7A-1F08-4CDB-8F55-B7D5B7BC3CDE Q34762064-28CEE0CE-3F5E-494D-841B-4D9BA943554B Q36444574-82D5AEA6-96A4-425D-B88C-614B65B17AF6 Q36534889-6D5F73D2-3D4E-47CE-BD3B-1CCA3F84C07C Q36576472-057A5481-99E8-4669-874B-A0A5B1B91A30 Q36998379-B29581C9-A7E8-4218-A0EF-399A14CBB30D Q37286287-69E3E66E-417D-4933-AD63-5BC65327D008 Q38086651-C6668C13-9F7B-497C-A5F3-BDAF6D1A41B1 Q38087640-71A62EB6-A3A1-476E-8BC8-A7D45C6E7E45 Q38150708-1214AEDC-FAAB-4322-BFE8-442E83B8804E Q38286222-8F11A4AE-88F3-4962-825F-408CBF6477A9 Q38906350-F1D21E63-FFA8-4794-A651-5B6B63ABE215 Q41786451-921CF675-626B-4D1E-A1E6-4E5457ABD7C9 Q43245833-46A98508-5648-4016-A51E-E1CFA118F895 Q47177885-CA72B878-1787-4B97-BE33-6E741E2EE6D8 Q48254545-3102DED6-571D-4CA8-BC03-6548AC5E8A89 Q48850171-D8BD1060-5332-4CAC-8D90-F05AA24DC4B1 Q49798067-7C1300BC-CD2F-467F-8DC2-25E0956F67AA Q50457360-9840F0B0-64DD-4961-BFCB-4FB7DD43E0AE Q51651328-758B2578-EE8B-42E1-BDC9-7428AB8EBA71 Q55115784-C81532BC-40E9-4671-B69C-837FD792FE8F Q55364364-9A43ADB3-0A75-4E2C-AD0F-EF2BB3FDC795

P2860

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

http://www.wikidata.org/entity/Q33911859

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@ast

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@en

type

label

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@ast

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@en

prefLabel

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@ast

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@en

P1433

Q33911859-52364611-EFC7-4969-81D2-FC22D9F73D02

P1476

Q33911859-A4ED5D5B-5FBF-42C3-83A1-B0ABD534AF2C

P2093

Q33911859-04EFBD61-4CF3-4477-8816-92921515A82D

Q33911859-11FA0921-3528-4E22-B104-0EC571FDFA86

Q33911859-1B1CC47E-7653-4DB7-A046-A035A2444A40

Q33911859-4B217EF2-7C79-4A6C-9499-CF5A7A96D304

Q33911859-6C5C3F3C-9CAC-474B-AF17-18A62732F63C

Q33911859-7991EA20-ABDA-4AD0-A43E-F9953901D65C

Q33911859-A64B96F6-1F17-4087-BD3A-ED5E2C701CAC

Q33911859-ABC49A3E-5BFB-48F4-89C0-5B9857148BF0

Q33911859-ECA391D0-E8AD-4458-A1A9-275B6EE6AE86

P2860

Q33911859-1B7307EF-E675-47EB-8455-B617B45BD995

Q33911859-66A0277A-094D-43DA-BC46-E8D5738F4920

Q33911859-7819FC64-C581-4690-AC26-CFF57392DE13

Q33911859-8A93974C-283A-4E90-9A39-4B6F204090D0

Q33911859-BF8EBB48-CEBA-433A-8B86-3B706616B3AB

Q33911859-C1B06F47-4044-4AFA-A49D-1985AAA832B3

Q33911859-D1F42EE2-8B28-44EB-86E8-574B17E7094E

Q33911859-E6F935EF-E838-4779-8045-FC40FFFF5CC9

Q33911859-EB3A5578-3F14-4AFA-93CD-2C31A85E4FEC

Q33911859-F693F59C-C26A-44C1-9851-120EDFA9F59A

P2888

Q33911859-7C4DB7E6-5080-4EDF-977F-2763DC3CA75B

P304

Q33911859-5DE83E34-2AF8-451D-BCE6-97C9B4AB0253

P31

Q33911859-6F408C47-DCC8-4A71-91EE-38E209E6A4B4

P356

Q33911859-5F2CBF27-B73C-4F08-AFCD-083B6BE6D113

P478

Q33911859-5699A082-7723-4BCC-B051-B6F2CD8F575C

P577

Q33911859-B9B61A69-F127-40FB-BE74-8CE451B83E8D

P5875

Q33911859-775B9CC5-698F-4611-A669-788C9C79C8E7

P6179

Q33911859-44A527B0-602C-40F7-A8E1-CEF4EEDC55EF

P698

Q33911859-54E88C53-4427-4C25-830E-FCFDAFB12E56

P921

Q33911859-C2178CC6-C53C-474D-8AEA-C67AAF09EEBA

P932

Q33911859-40AFBB33-CDDE-43E3-A107-6FDF98F78E47

P356

1471-2377-11-57

P1433

P1476

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

@en

P2093

Andrew Satlin

http://www.w3.org/2001/XMLSchema#string

Elimor Brand-Schieber

http://www.w3.org/2001/XMLSchema#string

Felix Veloso

http://www.w3.org/2001/XMLSchema#string

Francesco Bibbiani

http://www.w3.org/2001/XMLSchema#string

Heng Zou

http://www.w3.org/2001/XMLSchema#string

Jane Yardley

http://www.w3.org/2001/XMLSchema#string

Margaret Moline

http://www.w3.org/2001/XMLSchema#string

Martin Farlow

http://www.w3.org/2001/XMLSchema#string

Timothy Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

P2888

1471-2377-11-57

P304

57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2377-11-57

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51165288

http://www.w3.org/2001/XMLSchema#string

P6179

1026613692

http://www.w3.org/2001/XMLSchema#string

P698

21612646

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3126705

http://www.w3.org/2001/XMLSchema#string